ATRA Atara Biotherapeutics
- 0.690
- -0.010-1.40%
- 0.710
- +0.020+2.90%
Atara Biotherapeutics News
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
Atara Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 220.29% Stifel $4.8 → $2.3 Maintains Hold 11/10/2023 -30.37% Goldman Sachs $3 → $0.5 Maintains
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating.
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
Atara Biotherapeutics' Profitability Hinges on Partners' Success With Ebvallo Amid Market Challenges
Atara Biotherapeutics (ATRA) Gets a Buy From TD Cowen
Atara Biotherapeutics GAAP EPS of -$0.56 Misses by $0.03, Revenue of $4.25M Misses by $10.01M
Atara Biotherapeutics 4Q Loss/Shr 56c >ATRA
Atara Biotherapeutics 4Q Loss/Shr 56c >ATRA
Press Release: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Tab-cel(R) U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA MeetingAllogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans to Initiate an ATA3219 Lupus Nephritis Study
12 Health Care Stocks Moving In Friday's After-Market Session
GainersTalphera (NASDAQ:TLPH) shares moved upwards by 15.6% to $1.3 during Friday's after-market session. The company's market cap stands at $22.0 million. As per the news, the Q4 earnings report came
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersSCWorx (NASDAQ:WORX) stock increased by 60.8% to $2.75 during Wednesday's after-market session. The market value of their outstanding shares is at $3.3 million. IO Biotech (NASDAQ:IOBT) stock i
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA), Moderna (MRNA) and Madrigal Pharmaceuticals (MDGL)
Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy
Atara Biotherapeutics (ATRA) said Thursday it has received the US Food and Drug Administration's approval for an investigational new drug application for ATA3219, an allogeneic, anti-CD19 chimeric ant
FDA Clears Atara to Begin Phase 1 Study for Lupus Nephritis Drug
Express News | Atara Biotherapeutics Receives FDA Clearance Of IND Application In Lupus Nephritis For ATA3219
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
Atara Biotherapeutics Restructures, CMO Transitions to Consultant
Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis
Atara Biotherapeutics (ATRA) said Wednesday it submitted an investigational new drug application to the US Food and Drug Administration seeking approval for ATA3219 as a standalone treatment for syste
Analysis
Price Target
No Data
